ReviewHepatology communications2026
Immune mechanisms and pathophysiology of T cell-mediated pediatric acute liver failure (TC-PALF).
Review in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Immune dysregulation in pediatric acute liver failure (PALF) is a distinct phenomenon that has garnered interest with respect to disease outcomes and targeted therapies. Some patients with PALF have an "indeterminate" (iPALF) etiology ranging from acute severe hepatitis to fulminant liver failure. Recent evidence from iPALF demonstrates that a large subset suffers from a unified, immune-mediated disorder. This immune-mediated PALF has been defined by the presence of dense T-cell infiltrates on liver biopsy and is often referred to as T-cell PALF (TC-PALF). TC-PALF has common features with other inflammatory liver diseases, including autoimmune hepatitis, hemophagocytic lymphohistiocytosis, and macrophage activation syndrome, while also demonstrating distinct pathologic features that contribute to liver injury in PALF. In this review, the spectrum of disease, comparisons between young and aged liver immune microenvironments, and the current literature evaluating the immune system during PALF are summarized. Relationships between TC-PALF, other inflammatory liver diseases, and contemporary studies that associate specific immune subsets with this pathology are also reviewed. These studies use precision "omic" technologies to investigate tissue and blood samples in TC-PALF and have opened new lines of investigation into potential genetic, immunologic, and environmental risk factors for disease. Together, recent data suggest that immune dysregulation is a central feature of TC-PALF, and facets of disease offer potential biomarker identification to aid in the clinical management of TC-PALF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.